Jan G. J. Van De Winkel

Jan G. J. Van De Winkel's AcademicInfluence.com Rankings

Biology

#13344

World Rank

#16889

Historical Rank

Immunology

#921

World Rank

#945

Historical Rank

biology Degrees

Download Badge

Biology

Jan G. J. Van De Winkel's Degrees

PhD Immunology Utrecht University

Why Is Jan G. J. Van De Winkel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan G. J. Van De Winkel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange (2007) (854)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors (2011) (801)
Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. (1993) (711)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. (2004) (660)
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 (2006) (600)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface (2014) (553)
A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. (1991) (488)
The Fc receptor γ‐chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen (1997) (472)
IgA Fc receptors. (2003) (430)
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. (1992) (362)
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. (2002) (333)
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. (2002) (328)
IgA and the IgA Fc receptor. (2001) (308)
Molecular basis for a polymorphism of human Fc gamma receptor II (CD32) (1990) (299)
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. (2005) (287)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange (2013) (248)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1 (2009) (242)
Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 (2001) (239)
Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. (1996) (217)
Inflammation in autoimmunity: receptors for IgG revisited. (2001) (213)
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage (2009) (211)
FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. (2003) (209)
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. (2008) (207)
Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fc gamma receptor III on human neutrophils. Possible role of lectin-like interactions. (1993) (206)
Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. (1995) (205)
Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. (2001) (203)
Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. (1994) (198)
FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. (2006) (192)
Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. (2001) (189)
Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils (1995) (183)
Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. (2003) (183)
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. (1996) (181)
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy (2004) (174)
IgG receptor polymorphisms: risk factors for disease (1998) (168)
Renaissance of cancer therapeutic antibodies. (2003) (164)
Functional Characteristics of the High Affinity IgG Receptor, FcγRI (2011) (159)
Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism. (1998) (157)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. (2008) (156)
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). (1998) (152)
Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. (1994) (149)
The p85 Subunit of Phosphatidylinositol 3-Kinase Associates with the Fc Receptor γ-Chain and Linker for Activitor of T Cells (LAT) in Platelets Stimulated by Collagen and Convulxin* (1998) (145)
Structure and function of human IgA Fc receptors (Fc alpha R). (1996) (144)
Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors1 (2005) (144)
Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. (2000) (144)
IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis1 (2008) (142)
Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. (1998) (136)
Identification of signaling motifs within human Fc gamma RIIa and Fc gamma RIIb isoforms. (1995) (136)
FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. (1996) (132)
Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. (1999) (132)
Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis1 (2008) (130)
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. (2010) (129)
Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase. (1990) (129)
Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. (1993) (127)
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. (2006) (124)
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. (1997) (118)
Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. (1991) (115)
The Importance of Human FcγRI in Mediating Protection to Malaria (2007) (114)
The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. (1993) (113)
Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells (2011) (112)
Relevance of immunoglobulin G Fc receptor polymorphism to recurrence of adult periodontitis in Japanese patients (1997) (112)
Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3–CH3 Interaction Strength (2011) (111)
The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. (2006) (111)
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. (1996) (111)
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. (2003) (106)
Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. (1998) (105)
Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. (1994) (103)
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. (2002) (102)
CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. (2003) (100)
Role of pulmonary surfactant protein D in innate defense against Candida albicans. (2000) (99)
IgA EGFR antibodies mediate tumour killing in vivo (2013) (99)
Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. (1999) (94)
Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. (1992) (94)
N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG (2009) (90)
Structure of the gene for the human myeloid IgA Fc receptor (CD89). (1995) (88)
Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. (2011) (87)
Fcγ receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms (2002) (83)
Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor1 (2007) (83)
Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. (2003) (81)
Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. (1999) (81)
Role of Fc receptor gamma chain in inflammation and cartilage damage during experimental antigen-induced arthritis. (2000) (81)
Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. (1993) (81)
Macrophages play a dual role during pulmonary tuberculosis in mice. (2005) (78)
The Fcγ Receptor Genotype as a Risk Factor for Generalized Early-Onset Periodontitis in Japanese Patients. (2000) (78)
A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. (2004) (77)
Fcgamma receptor polymorphisms in relation to periodontitis. (2003) (77)
Central Role of Complement in Passive Protection by Human IgG1 and IgG2 Anti-pneumococcal Antibodies in Mice1 (2003) (77)
Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. (2003) (76)
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer (2003) (76)
Immunoglobulin-binding Sites of Human FcαRI (CD89) and Bovine Fcγ2R Are Located in their Membrane-distal Extracellular Domains (1999) (75)
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. (1998) (74)
Human low-affinity IgG receptor Fc gamma RIIa (CD32) introduced into mouse fibroblasts mediates phagocytosis of sensitized erythrocytes. (1992) (74)
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden (2011) (73)
Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). (1999) (72)
The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility (2008) (72)
Fc receptor and complement receptor-mediated phagocytosis in host defence. (1998) (72)
Functional differences between two Fc receptor ITAM signaling motifs. (1995) (70)
Human IgG Fc receptors. (1997) (70)
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. (2001) (68)
The Fcγ Receptor Genotype as a Severity Factor for Chronic Periodontitis in Japanese Patients. (2001) (68)
Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. (1993) (67)
Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis. (2001) (67)
CR3 (alphaM beta2; CD11b/CD18) restores IgG-dependent phagocytosis in transfectants expressing a phagocytosis-defective Fc gammaRIIA (CD32) tail-minus mutant. (1996) (67)
Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor gamma-chain signaling. (2001) (66)
Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing (2011) (65)
Mac-1 (CD11b/CD18) as Accessory Molecule for FcαR (CD89) Binding of IgA1 (2002) (63)
Proteolysis induces increased binding affinity of the monocyte type II FcR for human IgG. (1989) (62)
Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. (2003) (62)
Novel human antibody therapeutics: The age of the Umabs (2008) (62)
Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. (2004) (61)
Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. (2005) (61)
Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. (2000) (60)
Relevance of IgG receptor IIIb (CD16) polymorphism to handling of Porphyromonas gingivalis: implications for the pathogenesis of adult periodontitis. (2000) (60)
Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). (2000) (59)
Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between FcγRI and FcγRIV1 (2008) (59)
Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. (1992) (59)
Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. (2010) (59)
Liposomal Meningococcal B Vaccination: Role of Dendritic Cell Targeting in the Development of a Protective Immune Response (2003) (58)
Crosslinking of the human Fc receptor for IgA (FcalphaRI/CD89) triggers FcR gamma-chain-dependent shedding of soluble CD89. (1999) (58)
FcgammaR expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA) (2000) (58)
Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. (1997) (55)
Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. (2003) (55)
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. (1997) (53)
Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. (1993) (53)
Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. (1994) (52)
Clinical relevance of Fc gamma receptor polymorphisms. (1997) (52)
Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. (2001) (52)
Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition (2011) (51)
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. (1997) (51)
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. (2011) (50)
CD64-Directed Immunotoxin Inhibits Arthritis in a Novel CD64 Transgenic Rat Model1 (2006) (50)
Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity (2012) (50)
Human antibodies as next generation therapeutics. (2001) (50)
Immunotherapeutic potential of bispecific antibodies. (1997) (50)
Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. (1998) (49)
Gene organization of the human high affinity receptor for IgG, Fc gamma RI (CD64). Characterization and evidence for a second gene. (1991) (49)
Immunotherapeutic perspective for bispecific antibodies. (2000) (47)
Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. (2003) (45)
Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system (2010) (44)
Staphylococcus aureus Formyl Peptide Receptor–like 1 Inhibitor (FLIPr) and Its Homologue FLIPr-like Are Potent FcγR Antagonists That Inhibit IgG-Mediated Effector Functions (2013) (44)
Molecular basis for a familial defect in phagocyte expression of IgG receptor I (CD64). (1995) (41)
Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. (2003) (41)
Evidence for an intracellular niche for Bordetella pertussis in broncho-alveolar lavage cells of mice. (1999) (41)
Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. (2006) (37)
The cytoplasmic domain of FcgammaRIIA (CD32) participates in phagolysosome formation. (2001) (37)
G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). (1995) (36)
Teasing apart structural determinants of `toxicity' and `adjuvanticity': implications for meningococcal vaccine development (2004) (35)
A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. (2000) (35)
Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89). (2001) (34)
Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? (2002) (34)
Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer (1997) (33)
Granulocyte–macropha ge colony‐stimulating factor down‐regulates CD14 expression on monocytes (1996) (33)
Modulation of FcγRI (CD64) Ligand Binding by Blocking Peptides of Periplakin* (2004) (33)
Functional Association between the Human Myeloid Immunoglobulin A Fc Receptor (CD89) and FcR γChain (1995) (33)
Heterogeneity of human IgG Fc receptors. (1994) (33)
Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism. (1995) (33)
Filamin A Stabilizes FcγRI Surface Expression and Prevents Its Lysosomal Routing1 (2008) (33)
Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. (2003) (33)
Signaling through Mutants of the IgA Receptor CD89 and Consequences for Fc Receptor γ-Chain Interaction1 (2006) (32)
Interaction between hybrid mouse monoclonal antibodies and the human high-affinity IgG FcR, huFc gamma RI, on U937. Involvement of only one of the mIgG heavy chains in receptor binding. (1989) (32)
Enhanced FcαRI‐mediated neutrophil migration towards tumour colonies in the presence of endothelial cells (2012) (31)
The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. (1999) (31)
Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors (2003) (30)
Complement‐mediated tumor‐specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII) (2011) (30)
Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes. (2001) (30)
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells (2016) (29)
HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis (2010) (29)
Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. (1994) (28)
FcgammaRI (CD64) resides constitutively in lipid rafts. (2008) (28)
Effective Targeting of Pathogens to Neutrophils via Chimeric Surfactant Protein D/Anti-CD89 Protein1 (2004) (28)
Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils. (1999) (27)
Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. (1999) (27)
The Fc gamma receptor genotype as a severity factor for chronic periodontitis in Japanese patients. (2001) (27)
Evidence for non-random distribution of Fcgamma receptor genotype combinations. (2003) (26)
Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcγRI-calicheamicin immunoconjugate (2004) (26)
On the interaction between agalactosyl IgG and Fcγ receptors (1996) (26)
FcgammaRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. (2009) (25)
Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations (2008) (25)
The R-H polymorphism of FCgamma receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter. (2002) (25)
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. (2005) (24)
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30 (2014) (24)
FcR γ-Chain Dependent Signaling in Immature Neutrophils Is Mediated by FcαRI, but Not by FcγRI1 (2007) (24)
CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes. (1992) (23)
Working Mechanism of Immunoglobulin A1 (IgA1) Protease: Cleavage of IgA1 Antibody to Neisseria meningitidis PorA Requires De Novo Synthesis of IgA1 Protease (2005) (22)
Induction of intracellular Ca2+ mobilization and cytotoxicity by hybrid mouse monoclonal antibodies. Fc gamma RII regulation of Fc gamma RI-triggered functions or signaling? (1991) (22)
Clinical perspectives of bispecific antibodies in cancer (1997) (22)
An integrated science-based approach to drug development. (2008) (21)
The alternatively spliced CD64 transcript FcγRIb2 does not specify a surface‐expressed isoform (1999) (21)
The Fcgamma receptor genotype as a risk factor for generalized early-onset periodontitis in Japanese patients. (2000) (21)
HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies. (1997) (21)
Molecular engineering to improve antibodies' anti-lymphoma activity. (2011) (20)
The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. (1999) (20)
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. (2011) (20)
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. (2012) (20)
Effect of recombinant IFN-gamma (rIFN-gamma) on the mechanism of human macrophage IgG FcRI-mediated cytotoxicity. rIFN-gamma decreases inhibition by cytophilic human IgG and changes the cytolytic mechanism. (1992) (20)
The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP119) (2011) (19)
Inside-Out Regulation of FcαRI (CD89) Depends on PP2A1 (2008) (19)
Immunoadjuvant activity of a liposomal IL-6 formulation. (1993) (19)
Selective modulation of two human monocyte Fc receptors for IgG by immobilized immune complexes. (1988) (18)
The role of FcR in immunity: lessons from gene targeting in mice. (1997) (18)
CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells. (2004) (18)
CD20‐Specific Immunoligands Engaging NKG2D Enhance γδ T Cell‐Mediated Lysis of Lymphoma Cells (2017) (17)
Effect of protease inhibitors on human monocyte IgG Fc receptor II. Evidence that serine esterase activity is essential for Fc gamma RII-mediated binding. (1990) (17)
Granulocyte-macrophage colony-stimulating factor antagonizes the transforming growth factor-beta-induced expression of Fc gamma RIII (CD16) on human monocytes. (1996) (17)
Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA. (2002) (17)
Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin. (2004) (16)
Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils. (2004) (16)
Analysis of factors contributing to the formation of mononuclear cell aggregates ("escapees") in flow cytometric immunophenotyping. (1997) (16)
Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. (2003) (15)
The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE. (2005) (15)
Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. (2003) (15)
Inefficient antigen presentation via the IgA Fc receptor (FcalphaRI) on dendritic cells. (2006) (15)
Role of leukocyte immunoglobuin G receptors in vaccine-induced immunity to Streptococcus pneumoniae. (2003) (15)
Identification and structural characterization of Fc gamma-receptors on pulmonary alveolar macrophages. (1991) (14)
Protein 4.1G binds to a unique motif within the Fc gamma RI cytoplasmic tail. (2008) (14)
A flow cytometric rosetting assay for the analysis of IgG-Fc receptor interactions. (1990) (13)
Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating Fcgamma receptor I on monocytes. (2008) (13)
Alternatively spliced forms of the human myeloid Fc alpha receptor (CD89) in neutrophils. (1996) (13)
Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects. (1992) (12)
A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics. (1995) (12)
A new photometric method for the quantitation of Fc receptors for murine IgG1 on human monocytes and cell lines. (1987) (12)
Phagocytosis and intracellular killing of serum-opsonized Staphylococcus aureus by mouse fibroblasts expressing human Fcgamma receptor type IIa (CD32). (1996) (12)
Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele (2012) (11)
Interaction of a human Fc gamma RIIb1 (CD32) isoform with murine and human IgG subclasses. (1993) (11)
Fcgamma receptor polymorphisms and periodontal status: a prospective follow-up study. (2006) (11)
A new radiometric assay for the quantitation of surface-bound IgG on sensitized erythrocytes. (1988) (10)
Effector functions of IgG subclass antibodies. (1993) (10)
IGG and complement receptor expression on peripheral white blood cells in uraemic children. (2004) (9)
Flow cytometric determination of FcgammaRIIa (CD32) polymorphism. (2004) (9)
A single injection of polyethylene-glycol granulocyte colony-stimulating factor strongly prolongs survival of mice with systemic candidiasis. (2000) (9)
Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history? (2003) (9)
Evidence for a novel polymorphism affecting both N-linked glycosylation and ligand binding of the IgG receptor IIIB (CD16). (2001) (9)
The alternatively spliced CD64 transcript FcgammaRIb2 does not specify a surface-expressed isoform. (1999) (9)
No association of Fc gamma RIIa, Fc gamma RIIIa and Fc gamma RIIIb polymorphisms with MS. (2003) (8)
Functional polymorphism of IgG FcRII (CD32) on human neutrophils. (1990) (8)
Human monocyte-mediated cytotoxicity towards erythrocytes induced by hybrid mouse monoclonal antibodies: effect of antibody binding valency on IgG-Fc gamma R interaction. (1992) (7)
Retraction for Lammerts van Bueren et al., The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility (2012) (7)
Lysis of murine B lymphoma cells by transgenic phagocytes via a human FcγRI×murine MHC class II bispecific antibody (1997) (7)
Fc gamma IIA receptor phenotype and opsonophagocytosis in two patients with recurrent bacterial infections. (1993) (6)
On the interaction between agalactosyl IgG and Fc gamma receptors. (1996) (6)
Neutrophil Fc gamma RI as target for immunotherapy of invasive candidiasis. (2001) (6)
PMN-derived proteases enhance the affinity of Fc gamma receptor II on myeloid cells, but not on B cells. (1990) (6)
Characterization of the human myeloid IgA Fc receptor I (CD89) gene in a cosmid clone (1999) (5)
Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. (2008) (5)
Fc receptors: role in biology and antibody therapy. (2010) (5)
The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation. (2005) (5)
[Immunology in clinical practice. X. IgG receptors: structure, function and immunotherapy]. (1998) (4)
GM-CSF as adjuvant for immunotherapy with bispecific antibodies. (1999) (3)
Immunohistologic staining of renal transplant biopsies with monoclonal antibody WT14: a new parameter for the diagnosis of rejection. (1989) (3)
Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. (1994) (3)
Functional consequences of the interaction between T-cell antigen receptors and Fc gamma Rs on T cells. (1995) (3)
A novel polymorphism of FcalphaRI (CD89) associated with aggressive periodontitis. (2004) (3)
Impact of antibody Fc carbohydrate fucosylation on antibody-dependent cellular cytotoxicity by HuMax-EGFr -A fully human epidermal growth factor receptor antibody. (2006) (3)
Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody. (1997) (2)
Assignment of three human high-affinity Fc gamma receptor I genes to chromosome 1, band q21.1. (1993) (2)
FcgammaRIa-gamma-chain complexes trigger antibody-dependent cell-mediated cytotoxicity (ADCC) in CD5+ B cell/macrophage IIA1.6 cells. (1998) (2)
Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6. (1993) (2)
Human Fc gamma receptor II: a standby receptor activated by proteolysis? (1990) (2)
[Immunology in clinical practice. XI. IgG receptors: the role of polymorphism in autoimmune and infectious diseases]. (1998) (1)
Biological functioning of human IgG Fc receptors. (1990) (1)
Effect of the epidermal growth factor receptor antibody panitumumab on triggering of ADCC. (2009) (1)
Neutrophil FcγRI as Target for Immunotherapy of Invasive Candidiasis (2001) (0)
Effector proteins of FcγRI: inside-out and outside-in regulation (134.81) (2009) (0)
The role of epidermal growth factor receptor (EGFR)-directed recombinant dimeric IgA antibodies in tumor cell killing. (2011) (0)

This paper list is powered by the following services:

Jan G. J. Van De Winkel's Academic­Influence.com Rankings

Jan G. J. Van De Winkel's Degrees

Why Is Jan G. J. Van De Winkel Influential?

Jan G. J. Van De Winkel's Published Works

Published Works

Jan G. J. Van De Winkel's AcademicInfluence.com Rankings